Naltrexone

Research use only, not for human use.

A potent, competitive antagonist for μ, κ, δ, and σ-opioid receptors with Ki of 0.0825 nM, 0.509 nM, and 8.02 nM, for MOR, KOR, and DOR, respectively.

A potent, competitive antagonist for μ, κ, δ, and σ-opioid receptors with Ki of 0.0825 nM, 0.509 nM, and 8.02 nM, for MOR, KOR, and DOR, respectively; also inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular TLRs; a TLR-4 antognist that inhibits LPS-induced TLR4 downstream NO production in microglia BV-2 cells (IC50=105 uM).Alcoholism Approved.

——

——

——

Endocrinology/Hormones

Opioid Receptor

Opioid Receptor

Neurological Disease

Alcoholism

16590-41-3

341.4009

C20H23NO4

>98% (HPLC)

DMSO: ≥ 31 mg/mL

C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O

Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)-

(-20℃)

With Ice Pack

≥ 2 years